Nextgen-Biomed is a pharmaceutical company holding 98.6% of Dermipsor which develops topical treatment for Psoriasis. Dermipsor was founded in 2004 based on the invention of Dr. Avikam Harel, head of pediatric dermatology at Ichilov Hospital.
The company completed phase IIB feasibility study, accomplished preparing the FDA outline for Phase III clinical trial and is gearing towards Phase II/III clinical trial.
The company operates in a potential market estimated at over a billion USD a year.
Meet Our Team
Formerly a Senior Director with Teva Pharmaceutical Industries Ltd. Modi is a Corporate Development professional with well-rounded experience of more than 10 years, accounted primarily for an extensive M&A activity, as well as BD, strategy, S&M and variety of cross-organizational initiatives. Recently repatriated, after 3-years assignment for Teva USA.
Prof. Mark Lebwohl
Chairman of Scientific Board
Chairman of Dermatology at Mount Sinai Hospital, NYC, and chairman of the National Psoriasis Foundation Medical Board. He is an advisor to the largest pharmaceutical companies in the psoriasis field and is a globally renown opinion leader.
Dr. Avikam Harel
Dermipsor entrepreneur, a dermatology expert, Head of Dermatology (pediatrics) at Dana Children’s Hospital, Ichilov, and founder of the Israeli association for children’s dermatology.